201 related articles for article (PubMed ID: 20482675)
1. The biologic importance of tumor-infiltrating lymphocytes.
Hodi FS; Dranoff G
J Cutan Pathol; 2010 Apr; 37 Suppl 1(0 1):48-53. PubMed ID: 20482675
[TBL] [Abstract][Full Text] [Related]
2. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
Hodi FS; Butler M; Oble DA; Seiden MV; Haluska FG; Kruse A; Macrae S; Nelson M; Canning C; Lowy I; Korman A; Lautz D; Russell S; Jaklitsch MT; Ramaiya N; Chen TC; Neuberg D; Allison JP; Mihm MC; Dranoff G
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3005-10. PubMed ID: 18287062
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
4. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
[TBL] [Abstract][Full Text] [Related]
5. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
7. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
8. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
10. Active immunotherapy induces antibody responses that target tumor angiogenesis.
Schoenfeld J; Jinushi M; Nakazaki Y; Wiener D; Park J; Soiffer R; Neuberg D; Mihm M; Hodi FS; Dranoff G
Cancer Res; 2010 Dec; 70(24):10150-60. PubMed ID: 21159637
[TBL] [Abstract][Full Text] [Related]
11. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
12. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
14. Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma.
Domingo-Musibay E; Heun JM; Nevala WK; Callstrom M; Atwell T; Galanis E; Erickson LA; Markovic SN
Oncologist; 2017 Sep; 22(9):1026-e93. PubMed ID: 28679643
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
Soiffer R; Lynch T; Mihm M; Jung K; Rhuda C; Schmollinger JC; Hodi FS; Liebster L; Lam P; Mentzer S; Singer S; Tanabe KK; Cosimi AB; Duda R; Sober A; Bhan A; Daley J; Neuberg D; Parry G; Rokovich J; Richards L; Drayer J; Berns A; Clift S; Cohen LK; Mulligan RC; Dranoff G
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13141-6. PubMed ID: 9789055
[TBL] [Abstract][Full Text] [Related]
16. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
17. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy.
Zehntner S; Townsend W; Parkes J; Schmidt C; Down M; Bell J; Mulligan R; O'Rourke M; Ellem K; Thomas R
Pathology; 1999 May; 31(2):116-22. PubMed ID: 10399166
[TBL] [Abstract][Full Text] [Related]
18. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]